VANCOUVER, British Columbia / Aug 29, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:
Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
| Last Trade: | US$5.91 |
| Daily Change: | -0.26 -4.21 |
| Daily Volume: | 5,491,457 |
| Market Cap: | US$1.770B |
August 07, 2025 May 30, 2025 May 12, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
